Uman Albumin 200g/l Solution for infusion (50ml vial) माल्टा - अंग्रेज़ी - Malta Medicines Authority

uman albumin 200g/l solution for infusion (50ml vial)

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - albumin, human - solution for infusion - albumin, human 20 g/100ml - blood substitutes and perfusion solutions

Uman Albumin 200g/l Solution for infusion (100ml vial) माल्टा - अंग्रेज़ी - Malta Medicines Authority

uman albumin 200g/l solution for infusion (100ml vial)

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - albumin, human - solution for infusion - albumin, human 20 g/100ml - blood substitutes and perfusion solutions

Human Albumin Grifols 50 g/l solution for infusion आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

human albumin grifols 50 g/l solution for infusion

instituto grifols s.a. - human plasma protein - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin

ALBUMEX 20 albumin (human) 20g/100mL injection vial ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

albumex 20 albumin (human) 20g/100ml injection vial

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: octanoate; sodium; water for injections - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

ALBUMEX 20 albumin (human) 2g/10mL injection vial ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

albumex 20 albumin (human) 2g/10ml injection vial

csl behring australia pty ltd - albumin, quantity: 0.2 g/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium; octanoate - indications as at 27 january 2000: hypoproteinaemia in the acutely ill patient: albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4-5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. inititally (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome

PLASBUMIN (albumin- human solution संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

plasbumin (albumin- human solution

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - emergency treatment of hypovolemic shock plasbumin-20 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (plasbumin® -5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g per kg body weight in the absence of active bleeding. although plasbumin-5 is to be preferred for the usual volume deficits, plasbumin-20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic flu

ALBUKED (albumin- human solution संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

albuked (albumin- human solution

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - emergency treatment of hypovolemic shock albuked 25 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (albuked™ 5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual, i.e., about 2 g per kg body weight in the absence of active bleeding. although albuked 5 is to be preferred for the usual volume deficits, albuked 25 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic fluid from a